Article
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.
European journal of haematology - 1 May 2024
Eickhardt-Dalbøge Christina Schjellerup, Nielsen Henrik V, Fuursted Kurt, Stensvold Christen Rune, Andersen Lee O' Brien, Lilje Berit, Larsen Morten Kranker, Kjær Lasse, Christensen Sarah Friis, Knudsen Trine Alma, Skov Vibe, Sørensen Anders Lindholm, Ellervik Christina, Olsen Lars Rønn, Christensen Jens Jørgen Elmer, Nielsen Xiaohui Chen, Hasselbalch Hans Carl, Ingham Anna Cäcilia
Abstract excerpt
BACKGROUND: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis. METHODS: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.